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Specific adoptive  immunotherapy  is  a  theoretically  attractive  approach  to  the 
treatment  of tumors,  although  few  examples  exist  of the  effective treatment  of 
established syngeneic solid tumors by this approach  (1).  Early reports described the 
use of large numbers of thoracic duct lymphocytes from immunized animals  (2)  as 
well as lymphocytes from immunized allogeneic and  xenogeneic animals  (3)  in an 
attempt to eradicate solid tumors. Borberg et al. (4) treated Meth A sarcomas with up 
to 4 ×  109 immunized syngeneic lymphocytes and succeeded in causing regression of 
established tumors. Using the Meth A tumor, but an alternative method of immuni- 
zation, Berendt and North (5) demonstrated that the intravenous infusion of sensitized 
T  cells  from  immune  donors could cause complete regression  of large  established 
tumors growing in T  cell-deficient hosts. They also showed that infusion of splenic T 
cells from tumor-bearing donors could inhibit  this regression of established  tumor, 
suggesting that failure to reject this tumor was the result of suppressor T  cells in the 
tumor-bearing host.  Fernandez-Cruz et al.  (6)  showed that  intravenous infusion of 
immune lymphocytes was capable of curing irradiated rats bearing a  subcutaneous 
tumor. 
A  common factor in these adoptive immunotherapy investigations was the large 
number  of sensitized  lymphocytes  that  were  required  to  cause  the  regression  of 
established  solid tumors.  Because the expansion of lymphoid cells in  interleukin  2 
(IL-2) 1 is capable of generating large numbers of specifically immune cells, we have 
explored the possible use of these cells for the adoptive immunotherapy of a  solid 
tumor. T  lymphocytes expanded in IL-2 retain cytotoxic as well as other functional 
immunologic  properties,  and  individual  lymphocytes can  he  cloned  to  large  cell 
numbers without loss of immunologic specificity (7-11). Using these techniques, we 
have  demonstrated  that  specifically  sensitized  cells  expanded  in  lectin-free  IL-2 
(LF-IL-2) were capable of mediating allogeneic skin graft rejection (12)  when adop- 
tively transferred to normal hosts.  More recently, we have established long-term T 
lymphoid lines specifically lytic for the syngeneic FBL-3 lymphoma (13)  and  have 
successfully used these ceils in the adoptive chemoimmunotherapy of a disseminated 
micrometastatic tumor (14). 
1  Abbreviations  used in this paper: CM, conditioned  medium; Con A, concanavalin  A; FCS, fetal calf serum; 
HBSS, Hanks' balanced salt solution; IL-2, interleukin 2; IVS, in vitro sensitization; LF, lectin-free;  LSM, 
lymphocyte  separation medium. 
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In this paper we have extended these observations to the treatment of an established 
palpable syngeneic tumor in the footpad of C57BL/6 mice at a  time when the tumor 
is  also  disseminated  throughout  the  host.  We  have  demonstrated  that  immune 
lymphocytes, in vitro sensitized and expanded in LF-IL-2 as  a  sole treatment,  are 
effective in curing mice of both local tumors and disseminated metastases after one 
intravenous adoptive transfer. 
Materials and Methods 
Animals.  16-wk-old C57BL/6 mice were  used in these experiments. They were obtained 
from The Jackson Laboratory, Bar Harbor, ME. 
Tumors.  FBL-3 (kindly supplied to us by Dr. C. C. Ting, National Cancer Institute) is a 
Friend virus-induced lymphoma/leukemia transplanted in C57BL/6 mice in its ascitic form. 
This  tumor bears  tumor specific  and/or viral antigens that  cross-react  with  other  tumors 
induced by the Friend, Moloney, and Rauscher viruses (15) and grows well in the ascitic form 
in syngeneic mice. This tumor will grow and regress  in a normal C57BL/6 mouse if injected 
intramuscularly  or subcutaneously, although it grows progressively at these sites in irradiated 
mice. 
MCA-103 is a methylcholanthrene-induced  fibrosarcoma induced in C57BL/6 mice in our 
laboratory as previously described (16). It was maintained by serial intramuscular passage. 
In  Vivo Immunization.  8-12-wk-old C57BL/6 female mice were immunized with one intra- 
muscular injection of 107 live FBL-3 suspended in 0.05 ml sterile Hanks' balanced salt solution 
(HBSS). An intramuscular tumor will grow for ~2 wk and then completely regress. All animals 
used as immune spleen donors had no evidence of tumor at the time of spleen harvest. Less 
than 10% of the immunized animals grew tumors that resulted in the death of the animal. 
In Vivo Assay of  Adoptive lmmunotherapy.  Mice were given 500 rad whole-body irradiation (Cs 
137), and 2-4 h later 107 live FBL-3 tumor cells were injected into the right hind footpad in 
0.05 cc of sterile HBSS. 
By day 5 tumors were readily palpable and the footpad diameter measured between 2.5 and 
3 mm. Also by day 5 either the right popliteal lymph node or 0.75 ml of blood from tumor- 
bearing mice could cause progressive  tumor growth when injected intraperitoneally into a 
normal mouse that  had received 500 rad.  If left untreated, both the footpad tumor and its 
metastases grew and eventually killed the animal by 20 d after the initial tumor injection. 
5 d after tumor was induced, when the tumor was clearly measurable in all animals, mice 
were randomly assigned to treatment groups and injected intravenously with experimental or 
control cells in 1 cc of sterile HBSS. Each mouse was ear tagged and measured every 2nd or 3rd 
d  in  a  blinded fashion  without  knowledge of the  previous  treatment  or  of the  previous 
measurements for that mouse. 
Spleen Cell Suspension.  Spleens were aseptically removed, pooled, and crushed gently with 
the blunt end of a  10-cc syringe plunger in HBSS with  1% fetal calf serum (FCS). The cells 
were then centrifuged at 500 g for 5 min. The pellet was resuspended in buffered ammonium 
chloride solution (National Institutes of Health [NIH] Median Unit) for one minute at room 
temperature to lyse red blood cells. The cells were then washed three times in sterile HBSS and 
resuspended in complete medium (CM) before determination of cell viability  using trypan blue. 
CM was composed of RPMI 1640 (Grand Island Biological Co., Grand Island, NY) with 10% 
heat-inactivated FCS (Grand Island Biological  Co.),  1/xM sodium pyruvate (Microbiological 
Associates, Walkersville, MD), 0.1 mM nonessential amino acids (Microbiological Associates), 
0.03% fresh glutamine (NIH Media Unit), 5 ×  10  -s M 2-mercaptoethanol, 100 U/ml penicillin, 
and 100 gg/ml streptomycin. 
In  Vitro Sensitization (1VS):  Conditions for IVS have been previously described (13, 14). In 
brief, 6 ×  10  7 viable responder cells and l0  n irradiated stimulator cells were placed in upright 
flasks (3013; Costar, Data Packaging, Cambridge, MA) in 20 ml of CM. Stimulator cells were 
irradiated in a gamma irradiator (Cs 137) with 2000 rad for normal C57BL/6 lymphocytes or 
10,000 rad  for  fresh  FBL-3  tumor.  Cells were  harvested  on day  5  and  tested  in vitro for 
cytotoxicity, used in experiments or placed in IL-2. If the cells were injected in vivo, they were 
first placed on a 5 ml lymphocyte separation medium (LSM) gradient (Cedarlane Laboratories, T. J.  EBERLEIN,  M.  ROSENSTEIN, AND S. A.  ROSENBERG  387 
Ontario, Canada)  at  a  concentration of 107 cells/ml and  spun  at  1000  g  for 20  min.  The 
interface was then removed using a  pasteur pipette, and the cells were washed three times in 
HBSS,  passed over  100-mesh  nylon, counted,  and  injected. This technique  resulted  in  cell 
viability >95%. 
Production of LF-IL-2.  Optimal conditions for the production of IL-2 have been previously 
described (11). Briefly, exbreeder DBA/2 or BALB/c spleens were aseptically  harvested, minced, 
washed,  and  then  incubated with  10 pg/ml  eoncanavalin A  (Con  A)  (Miles Laboratories, 
Elkhart, IN) for 2 h. The cells were washed three times in HBSS and resuspended in CM for 
24 h at 37°C and 5% CO2. The resulting culture supernatants were harvested, centrifuged, and 
poured through 0.45-/~m filters (Millipore Corp., Bedford, MA). This LF-IL-2 was >95% Con 
A  free  as  determined  by  the  absence  of mitogenic  activity on  fresh  lymphoeytes and  by 
measurement of removal of radiolabeled Con A  (11). 
Expansion of IVS Lymphoid Cells.  Cells  were  aseptically harvested  from  the  IVS  flasks, 
centrifuged, and resuspended in fresh CM. Cell viability was assessed using trypan blue dye 
exclusion. The sensitized cells  4  were then adjusted to a concentration of 5 ×  10  viable cells/ml 
in  an  equal  volume of CM  and  LF-IL-2. This  final suspension was placed in  24-well  flat- 
bottomed plates (3524;  Costar), 2 ml/well. The cells expanded a  minimum of 8.5  times the 
original number in 7 d. If adoptively transferred, the cells were washed in HBSS three times, 
passed over 100-mesh nylon, counted, and adjusted to the desired concentration for injection. 
All injections were in 1 ml vol of HBSS. 
In the experiment using cells expanded multiple times in IL-2, the cells were harvested every 
5-7 d, centrifuged at 500g for 5 min, and readjusted to 5 ×  104 viable cells/ml in fresh CM:LF- 
IL-2. 105 irradiated FBL-3 tumor cells/ml (10,000  rad) were present in the culture from IVS 
until the final 10 d before adoptive transfer. Cells expanded in IL-2 were not placed on LSM 
gradients before adoptive transfer, and always had >95% viability. 
Chromium Release Cytotoxicity Assay.  An 18-h chromium release assay was used as previously 
described (8).  Briefly, varying ratios of effector cells were plated in 96-well round-bottomed 
4  51  plates (Linbro Chemical Co.,  Hamden,  CT)  with  10  viable  Cr-labeled tumor targets per 
well. The  plates were  then  centrifuged at  80 g  for 5  min,  incubated  at  37 °  for  18  h,  and 
recentrifuged at  400 g  for  10  rain, and  the supernatants were harvested using the Titertek 
Collecting System (Flow Laboratories, Rockville, MD). 
Fresh FBL-3 was harvested from the ascites of a tumor-bearing mouse, washed, and labeled 
with 51Cr. MCA-103 tumor was minced with fine scissors, trypsinized for 7 min, passed through 
double-layer 100-mesh nylon, and washed three times before 51Cr label. Spontaneous release 
for these experiments was -40%. In previous studies (13) MCA-103 was shown to be at least as 
lysable as FBL-3 by an allogeneic effector. 18-h assays revealed substantially higher and more 
reproducible levels of specific tumor lysis than were seen in 4-h 5XCr-release assays. 
e  Cytoxicity is expressed as lyric units/10  cells. A lytic unit is defined as the number of effector 
cells that causes 50% lysis of 104 5XCrolabeled target cells. 
Statistical Methods.  Survival of mice in these experiments was computed using the methods 
of Peto et al. (17).  To compare survival curves, mean survival time was MST calculated and 
Student's t-test used to determine P values. No animals were excluded from statistical evaluation. 
Results 
Treatment  of  Disseminated  FBL-3  with  In  Vivo Immunized  Lymphoid  Cells.  Adult 
C57BL/6 female mice were immunized to FBL-3 with one intramuscular injection of 
live FBL-3. Approximately 3-4 wk later, their spleens were harvested and tested in 
vitro  and  in  vivo.  In  every  experiment,  these  immune  cells  showed  no  in  vitro 
cytotoxicity for FBL-3 tumor in an  18-h 5XCr-release assay (data not  shown).  When 
these same cells were adoptively transferred to mice with disseminated footpad tumors, 
however, they conferred significant survival benefit when compared with no treatment 
or treatment with similar numbers of lymphocytes from normal syngeneic mice. Fig. 
1 is a  representative experiment of four experiments, each with a  similar result. The 
left panel shows the mean footpad tumor size of each group and the right panel the 388  REGRESSION  OF  A  DISSEMINATED  SYNGENEIC  SOLID  TUMOR 
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Fro.  t.  Footpad  tumor size  (left)  and  survival  (right)  of mice with disseminated solid  FBL-3 
lymphoma treated with in vivo immunized lymphocytes. Treatment with  10  s immune cells was 
necessary to completely eradicate footpad tumors and cure animals.  10  a normal lymphocytes or 
fewer immune lymphocytes were not capable of impacting significantly on tumor growth or survival. 
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corresponding survival curve. As seen in Fig.  1,  10  s immune cells given intravenously 
were required  to cure mice. In no experiment were 5  ×  107 immune cells effective. 
Combining all four experiments, 26 of 28 mice given 10  s immune cells were cured of 
tumor, whereas 3 of 17 mice with normal lymphocytes were cured  (P <  0.0005).  All 
20 untreated  animals died of disseminated  FBL-3 tumor  (P <  0.0005  compared to 
treatment with immune cells). 
Adoptive Transfer of In  Vitro Sensitized Lymphoid Cells before Expansion in LF-IL-2.  In 
vivo immunzed  lymphocytes were resensitized  to  irradiated  FBL-3  tumor in  vitro. 
Simultaneously,  nonimmune  lymphocytes were co-cultured  with  normal  C57BL/6 
irradiated stimulators in vitro. After 5 d  in culture, the cells were harvested, washed, 
placed on an LSM gradient, rewashed three times, counted, and adoptively transferred 
to mice that had been injected with tumor in the footpad 5 d  earlier. No more than 
5 ×  107 viable cells were transferred in any experiment. Before transfer, an aliquot of 
the cells was tested for in vitro cytotoxicity. 
Fig. 2 is a representative experiment (one of three) showing the levels of cytotoxicity 
attained  after in  vitro  sensitization.  Only  the  immune  cells  resensitized  to  FBL-3 
tumor in vitro showed specific lysis of fresh FBL-3 (91  lytie units).  Nonimmune cells 
co-cultured with normal lymphocytes showed nonspecific lysis, <5 lytic units, for both 
fresh FBL-3 and fresh MCA-103  targets.  Fig.  3 shows two of the three experiments 
using treatment with in vitro sensitized cells. In all three experiments,  11 of 14 mice 
treated with the immune cells resensitized to FBL-3 were cured of tumor, compared 
with  0  of  16  mice  treated  with  nonimmune  lymphocytes  resensitized  to  normal 
lymphocytes (P <  0.0005).  Once again, none of the  18  untreated  controls survived 
(P <  0.0005). 
Adoptive Transfer of Lymphoid Cells Expanded in LF-IL-2.  Cells were harvested from 
IVS flasks, washed, counted, and placed in LF-IL-2 at 5 ×  104 cells/ml. There was a 
minimum 8.5-fold expansion of cell number in 7 d. The cells were harvested from the 
expansion plates, washed three times, and adjusted to the appropriate cell number in 
1 cc of sterile  HBSS.  Fig.  4  shows  the  results  of one of three  similar experiments T. J.  EBERLEIN, M.  ROSENSTEIN, AND S.  A.  ROSENBERG  389 
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Fla.  2.  In vitro cytotoxicity of immune cells co-cultured with FBL-3 tumor for 5 d or nonimmune 
cells in vitro sensitized to normal C57BL/6 lymphocytes for 5 d. Resensitization of immune cells to 
FBL-3 tumor conferred specific cytotoxicity at the higher effector/target ratio (EFT). L.U., lytic 
units. 
demonstrating a high degree of specific lysis of fresh FBL-3 tumor. Immune lympho- 
cytes previously co-cultured  with  FBL-3 tumor and then expanded  8.5-fold  in  LF- 
IL-2 showed 2,000  lytic units against  fresh FBL-3 and <15  lytic units against  fresh 
MCA 103. Nonimmune, in vitro sensitized lymphocytes cultured in IL-2 for an equal 
length of time showed <5 lytic units when tested against either fresh tumor target. 
Nonimmune lymphocytes sensitized in vitro to FBL-3 tumor also demonstrated  no 
lysis of either tumor both before and after expansion in LF-IL-2 (data not shown). 
Fig.  5  shows  the  results  of the  first  experiment  with  the  adoptive  transfer  of 
expanded  cells  in  this  disseminated  footpad  tumor  model.  Immune  lymphocytes 
resensitized to FBL-3 tumor for 5  d  and then expanded 8.5-fold in LF-IL-2 for 7 d 
were capable of curing  11 of 12 mice treated with one intravenous injection of either 
5 X  107 or 2.5 ×  107 cells (P <  0.0005). The only mouse in these groups that died did 
so on day 42 without  evidence of tumor, and  this  animal received a  lower dose of 
effector cells  (2.5  ×  107). There was no significant  difference either in  footpad size 
(Fig.  5, left) or survival (Fig.  5, right)  between mice receiving 5  X  107 or 2.5  ×  107 
lymphocytes. Normal lymphoeytes expanded  in LF-IL-2 for 7 d  failed to have any 
impact on either footpad tumor size or survival. 
In  a  repeat  experiment,  the  adoptive  transfer  of cells  occurred  on  day  6  after 
injection of tumor in the footpad. Once again, immune lymphocytes co-cultured with 
FBL-3  tumor for 5  d  and  then  expanded  in  LF-IL-2 for  7  d  conferred  significant 
survival benefit (P <  0.0005), with all but one footpad tumor returning to normal by 
day 17. There was one death on day 31  in a  mouse with disseminated tumor. When 
these cells received 2,000 rad just before adoptive transfer (open squares, Fig. 6), the 
survival benefit  was  abrogated.  When  irradiated  cells were used,  no animals were 
cured, and the survival time was the same as in the untreated control group. Thus, it 390  REGRESSION OF A DISSEMINATED SYNGENEIC  SOLID TUMOR 
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Fro. 3.  Footpad tumor size (left graphs) and survival  (right graphs) of mice with disseminated 
solid syngeneic tumors treated with cells in vitro sensitized for 5 d in CM. Immune lymphocytes 
resensitized to FBL-3 tumor cured 9 of 10 animals in these two experiments. Nonimmune lympho- 
cytes eocuhured to normal C57BL/6 lymphocytes were no more effective than no treatment. 
appeared that a  cell capable of dividing in vivo was necessary to mediate an increase 
in survival. 
Table I shows the combined result of all three experiments performed with adoptive 
transfer of cells expanded in IL-2 for 1 wk. 5  ×  107 immune sensitized cells expanded 
in IL-2 cured 93% of all animals treated. 2.5 ×  107 cells cured 80% of the animals, and 
the one animal that died did so without evidence of tumor. A  dose of 5 X  106 immune 
expanded cells cured three of eight animals treated. Irradiation at 2,000 rad of these 
same cells totally abolished their effectiveness in vivo. Similarly, nonimmune sensitized 
and expanded cells cured none of the 11 animals so treated, and all of the 17 untreated 
control animals died. 
The  immune  cells in  Fig.  5  were  expanded  3,500-fold  in  LF-IL-2 for  ~  1  mo  as 
described in Materials and Methods. These cells maintained a  high degree of specific 
lysis of fresh FBL-3 tumor  (Fig.  7)  when  tested in an  18-h 5XCr release assay on  the 
day of adoptive  transfer  (3,571  lytic units).  These  same  cells conferred  significant 
survival benefit  (Fig. 8)  when  adoptively transferred.  Five of nine animals receiving 
5  ×  107  cells were  cured,  and  three  of seven  animals were  cured  at  a  dose  of  107 
transferred  cells  per  mouse  (P  .¢  0.01).  Nonimmune  lyrr,  phocytes  resensitized  to T. J.  EBERLEIN,  M.  ROSENSTEIN,  AND  S.  A.  ROSENBERG 
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FIG.  4.  In  vitro  cytotoxicity  of cells expanded  for  7  d  in  LF-IL-2.  Immune cells sensitized  to 
FBL-2 tumor and expanded in IL-2 showed increased specific lysis when compared to nonimmune 
lymphocytes sensitized to normal C57BL/6 lymphocytes and expanded in IL-2 for a similar period 
of time. L.U., lytic units. 
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Fro.  5.  Footpad  tumor size  (left)  and survival  (right)  of mice with  disseminated solid  tumors 
treated with cells expanded in IL-2 over 7 d. Immune cells sensitized to FBL-3 and expanded for 7 
d  in  IL-2 cured  all  mice treated,  and cured  80%  when a  reduced  dose of these cells was given. 
Nonimmune cells sensitized and then expanded in IL-2 for a similar period were no better than the 
no-treatment control group. 
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normal C57BL/6 stimulators and expanded in LF-IL-2 for the same length of time 
could not mediate the shrinkage of footpad tumors (Fig. 8, left) or impact on survival 
(Fig. 8, right). 
Discussion 
In the experiments reported in this paper, we have demonstrated that mice bearing 
a  palpable local and  disseminated  tumor could be cured by the systemic adoptive 392  REGRESSION OF A DISSEMINATED SYNGENEIC SOLID TUMOR 
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FIG. 6.  Footpad  tumor size (left) and survival (right) of mice with disseminated solid syngeneic 
tumors treated on day 6 with cells expanded in IL-2. Immune cells sensitized to FBL-3 tumor and 
then expanded in IL-2 for 7 d cured three of four mice treated; however, if these same cells were 
given 2,000 rad before transfer, their in vivo effectiveness  was abolished. 
TABLE  I 
Footpad  Survival  Percent  survival 
cures 
I a FBL-3 expanded* 
5 X 107  13  13/14  93% 
2.5 x  107  5  4/5  80% 
107  2  2/4  50% 
5 X 106  3  3/8  37.5% 
5 X 107 (2,000 rad)  0  0/4  0% 
NL a  NL expanded:t: 
5 X 107  0  0/11  0% 
No treatment  0  0/17  0% 
* Immune lymphocytes  resensitized  to FBL-3 tumor in vitro and expanded in 
LF-TCGF for 7 d. 
:~ Nonimmune lymphocytes resensitized to normal lymphocytes in vitro and 
then expanded for 7 d in LF-TCGF. 
transfer of a  single injection of in vivo immunized cells, in vitro sensitized cells, or 
sensitized cells  expanded  >3,000-fold  in  IL-2.  These  experiments  are  the  first  to 
demonstrate cure of a syngeneic solid tumor using cells expanded for many generations 
in  IL-2.  These  results  also  extend  our  previous  observations of the  treatment  of 
intraperitoneal FBL-3 tumor. We previously demonstrated (14)  that  a  combination 
of chemotherapy  and  adoptive  transfer  of sensitized  cells  expanded  in  IL-2  was 
capable of curing mice with disseminated and intraperitoneal FBL-3 tumor. Similar 
results were obtained by Cheever et al.  (18,  19). 
However, the interpretation of our previous studies (14) and those of others (18, 19) 
using the adoptive transfer of cells expanded in IL-2 to treat intraperitoneal FBL-3 
tumor were confused by the need for cytoreductive treatment of the tumor-bearing 
mouse  with  cyclophosphamide before  cell  transfer  and  by  the  need  to  inject  the 
transferred cells intraperitoneally at the site of major tumor growth. These problems 
led  us  to  develop  the  present  model,  in  which  expanded  lymphoid cells  injected 100 
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Fro.  7.  In vitro cytotoxicity of cells expanded  ~  1 mo in IL-2. Immune cells sensitized  to FBL-3 
tumor and expanded 3,500-fold in LF-IL-2 maintained specific lysis of fresh FBL-3 tumor. L.U., 
lytic units. 
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Fro.  8.  Footpad  tumor  size  (left)  and  survival  (right)  of mice with  disseminated  solid  FBL-3 
tumors treated with cells expanded in IL-2 for -  1 too. Immune cells sensitized to FBL-3 tumor and 
expanded 3,500-fold cured a significant number of mice at the high dose of cells transferred and low 
dose. No dose of similarly expanded control cells was capable of cure. 
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intravenously are used as sole therapy  to test the ability of cells expanded  in IL-2 to 
cure mice of syngeneic palpable and disseminated  tumor. 
This model has several important  advantages. The tumor being treated by adoptive 
transfer of cells is a  palpable solid tumor in the footpad of mice, and the regression of 
this  palpable  tumor  can  be  easily  followed  by  direct  measurement.  On  the  day  of 394  REGRESSION OF A DISSEMINATED SYNGENEIC SOLID TUMOR 
treatment, tumor is disseminated both in the blood and in the lymphatics, and thus 
treatment effects on local and distant  tumor can be evaluated. Tumor-bearing mice 
receive treatment with cells alone, and thus the potentially confusing cytoreductive 
effects of cyclophosphamide are avoided.  Another feature of our new model is that 
adoptive treatment with cells is administered intravenously and not into the site of 
the tumor. In previous studies of the treatment of intraperitoneal tumor, we (14)  and 
others  (18,  19)  injected effector cells intraperitoneally. The possibility existed, there- 
fore,  that  adoptively  transferred  cells  acted  mainly  in  local  tumor  neutralization, 
rather than systemic immunotherapy. 
Whole body preirradiation of mice is essential to enable growth of the FBL-3 tumor 
in  the footpad. The effect of this irradiation  on the therapeutic  effectiveness of the 
adoptively transferred lymphocytes is not known, but may be an important factor by 
eliminating suppressor cells. Berendt and North (5), showed that adoptive transfer of 
fresh immune lymphoid cells could cause the complete regression of large established 
tumors only if the  tumor bearers were T  cell deficient.  Furthermore,  these authors 
showed that infusion of splenic T  cells from tumor-bearing donors could inhibit  the 
regression of established tumor in T  cell-deficient recipients, confirming the impor- 
tance of host suppressor mechanisms in these tumor systems. 
In this paper, we have shown that lymph nodes and/or blood from a mouse bearing 
the  FBL-3  tumor 5  d  after tumor injection  are capable of transferring  tumor  to a 
normal, irradiated, C57BL/6 syngeneic recipient. The tumor is thus widely dissemi- 
nated  by day 5.  Treatment  of this  tumor with  in  vivo immunized  cells,  on  day 5, 
when it  is also clearly palpable, resulted  in cure of 93%  of all mice treated  in  four 
experiments.  As seen in  Fig.  1, however,  -10  a cells were required  to cure a  mouse. 
When these in vivo immunized cells were resensitized to FBL-3 in vitro for 5 d, cures 
could be achieved with smaller doses of ceils  (Fig.  3).  This finding emphasizes the 
value of in vitro sensitization in the activation/reactivation of cells that are necessary 
for successful adoptive immunotherapy (20). 
When  appropriately sensitized cells were expanded  in  LF-IL-2, they were highly 
lytic for fresh FBL-3 tumor in  vitro  (Figs.  4  and  7)  and capable of curing  mice of 
disseminated footpad tumors (Figs. 5 and 6). Indeed, in three experiments (as seen in 
Table I), expanded  cells adoptively transferred  to mice with  disseminated  footpad 
tumors cured mice when as few as 5 ×  106 cells were transferred. Cells grown in IL-2 
for  almost  1  mo  (3,500-fold  expansion)  were  also  capable  of curing  a  significant 
number of animals with disseminated footpad tumors (Fig. 8). Thus, through the use 
of IL-2, we have been able to expand the therapeutically effective cell to sufficient 
numbers to cure mice. 
The type of cell effecting the cure of tumor in this model is not known. It appears 
that  a  cell capable of proliferation  in  vivo is necessary, and  that  this proliferation 
takes  7-10 d  before a  critical  mass of effector cells is reached  to  impact on  tumor 
growth. Although the in vitro sensitized and expanded effector populations capable 
of curing animals in this model are cytotoxic for fresh FBL-3 tumor in vitro, there is 
a potential problem in selecting cells for use in adoptive immunotherapy based solely 
on in vitro reactivity. The primary effector cells in vivo in this model may not be the 
cytotoxic cell measured in our in vitro assays. Fernandez-Cruz et al.  (6)  showed that T. J. EBERLEIN, M.  ROSENSTEIN, AND S.  A.  ROSENBERG  395 
the  subset  of T  cells  most  effective  in  eradicating  rat  solid  tumors  in  vivo  were 
noncytotoxic in an in vitro 51Cr release assay. Supporting the hypothesis that a helper 
cell is the primary effector cell in mediating tissue rejection is the work of Loveland 
et  al.  (20,  21),  who  showed  that  skin  and  tumor  allograft  rejection  in  vivo  was 
dependent  on  the  presence  of Lyt-1  ÷  cells.  Greenberg  et  al.  (22)  reported  similar 
findings  used  in  vivo  immunized  cells  depleted  of  Lyt-2  ÷  cells  to  cure  mice  of 
disseminated FBL-3 tumor. Similar findings were obtained by Fernandez-Cruz  (23) 
in a syngeneic rat solid tumor model. Regardless of which cell is effective in our tumor 
model, we were able to increase the number of cells available for adoptive transfer 
using IL-2. 
The demonstration  that  intravenously  injected  lymphoid cells expanded  in  IL-2 
are  capable  of mediating  local  and  disseminated  tumor  regression  has  important 
implications for the adoptive immunotherapy of tumors. The abnormal traffic pat- 
terns seen when cells expanded in IL-2 are reinjected into mice and humans (24) have 
led  to concern  that  these expanded  cells would  not  be functional  when  injected  in 
vivo.  Our  previous  demonstration  that  intravenous  injection  of cells  expanded  in 
IL-2 was capable of accelerating the rejection of allogeneic skin grafts (12),  and the 
present  demonstration  that  syngeneic  tumors  could  be  made  to  regress  following 
intravenous  injection  of expanded  sensitized  cells  indicate  that  cells  expanded  in 
IL-2 can distribute appropriately and mediate immunologic tissue destruction follow- 
ing intravenous  injection.  Our current  efforts are directed  at  sensitizing autologous 
lymphoid cells  to human  tumors  in  the  hope that  expansion  of these cells will  be 
useful in the adoptive immunotherapy of human tumors. 
Summary 
We  have studied  the  ability  of immunized  lymphoid  cells  expanded  in  IL-2 to 
mediate the cure of mice with localized and disseminated syngeneic lymphoma. Mice 
received 500  rad  total-body irradiation  before injection  of tumor into  the  footpad. 
Mice were treated 5 d later when a palpable local tumor and disseminated metastases 
were present. Intravenous injection of in vivo immune lymphocytes cured 93% of all 
mice,  significantly  better  than  any  control  group  (P  <  0.0005).  Immune  cells, 
secondarily sensitized to the FBL-3 tumor in vitro, also conferred significant survival 
benefit (P <  0.0005) when injected intravenously, curing 79% of the animals treated. 
When these in vitro sensitized cells were expanded in IL-2, 8-10-fold over 7 d, 93% of 
the animals thus treated were cured,  (P <  0.0005).  When these cells were grown for 
multiple  generations  in  IL-2  they  retained  their  ability  to  cure  mice  (56%  cured, 
P <  0.01). This is the first demonstration that intravenous injection of sensitized cells 
grown in long term culture in IL-2 is capable of curing mice of established local and 
disseminated syngeneic tumor. 
Received  for publication 12 April 1982. 
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